ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 556

Depletion Of The Gut Microbiota Prevents β2-Glycoprotein I Antibody Production and Mortality In a Model Of Antiphospholipid Syndrome

Silvio M. Vieira1, Andrew Yu1, Odelya E. Pagovich1, Eleni Tiniakou2, John Sterpka1 and Martin A. Kriegel3,4, 1Yale School of Medicine, New Haven, CT, 2Yale University School of Medicine, New Haven, CT, 3Immunobiology, Yale School of Medicine, New Haven, CT, 4Medicine/Division of Rheumatology, Yale School of Medicine, New Haven, CT

Meeting: 2013 ACR/ARHP Annual Meeting

Keywords: Antibiotics, Antiphospholipid antibodies, heart disease and microbiome, Lupus

  • Tweet
  • Email
  • Print
Session Information

Title: Systemic Lupus Erythematosus - Animal Models

Session Type: Abstract Submissions (ACR)

Background/Purpose: Infectious triggers have been implicated in transient antiphospholipid antibody production in both mice and humans. The cause of persistent anti-β2-glycoprotein I (β2GPI) antibody production in the lupus-related antiphospholipid syndrome (APS) is unknown. We hypothesize that pathogenic antiphospholipid antibodies in the spontaneous (NZWxBXSB)F1 model of APS/SLE are induced and sustained by the gut microbiota that chronically colonizes its host. We therefore generated commensal-ablated animals in order to test if depletion of the microbiota with broad-spectrum antibiotics leads to attenuation of the APS phenotype characterized by multiple non-atherogenic, immune-mediated myocardial infarctions culminating in sudden deaths. 

Methods: Broad-spectrum antibiotic- and control water-treated (NZWxBXSB)F1 hybrid males were followed until death from autoimmunity. DNA was isolated from fecal pellets (MoBio) and tested for eubacterial load by 16S ribosomal DNA real-time PCR (Bio-Rad). Urine and sera were collected longitudinally and analysed for proteinuria from lupus-related glomerulonephritis and anti-β2-GPI titers by ELISA (Alpha Diagnostic), respectively. Hematoxylin and eosin-stained slides were prepared from myocardial tissues. Kaplan-Meier survival curves were generated comparing antibiotic- and control water-treated mice.

Results: 16S ribosomal DNA load was profoundly suppressed after treatment with a cocktail of vancomycin, metronidazole, neomycin and ampicillin that was initiated at 6 wks of age. Antibiotic-treated mice had significantly lower titers of anti-β2GPI antibodies at 4 months of age (p=0.014) and were protected from APS-related deaths (p=0.005). Ceca were markedly enlarged on necropsy as typical also for germ-free animals. Surprisingly, SLE-related proteinuria, known to be driven by an endogenous retroviral protein, was also suppressed in antibiotic-treated mice compared to controls (n=7-8 mice; p=0.026).

Conclusion: Depletion of the gut microbiota with a regimen that approximates a germ-free state in the gastrointestinal tract leads to lower anti-β2GPI titers and protection from APS-induced myocardial infarctions. These results suggest that gut commensals are fundamentally involved in the pathogenesis of APS. Intriguingly, endogenous retroviral-driven proteinuria secondary to lupus nephritis in the (NZWxBXSB)F1 hybrid was also suppressed by this regimen, pointing towards a possible interaction between the gut microbiota and retroviruses in systemic autoimmunity. These findings support an unexpected role of commensals in both APS and SLE. Future work is aimed at identifying the causal triggers within the gut microbiome and dissecting the immunologic mechanisms behind the protective effects in this model.


Disclosure:

S. M. Vieira,
None;

A. Yu,
None;

O. E. Pagovich,
None;

E. Tiniakou,
None;

J. Sterpka,
None;

M. A. Kriegel,
None.

  • Tweet
  • Email
  • Print

« Back to 2013 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/depletion-of-the-gut-microbiota-prevents-%ce%b22-glycoprotein-i-antibody-production-and-mortality-in-a-model-of-antiphospholipid-syndrome/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology